Literature DB >> 28248752

Radiofrequency ablation treatment for aldosterone-producing adenomas.

Barry A Sacks1, Ari C Sacks, Salomao Faintuch.   

Abstract

PURPOSE OF REVIEW: To review the current status of radiofrequency ablation as a primary treatment for hyperfunctioning adrenal nodules, predominantly aldosterone-producing adenomas (APAs). RECENT
FINDINGS: Radiofrequency ablation is an established treatment for focal benign and malignant lesions, including metastatic disease to the adrenal gland. Hyperaldosteronism is the leading cause of secondary hypertension with up to 80% due to APA, statistically the most common functioning adrenal nodule. Although surgery remains the recommended treatment of choice for confirmed unilateral functioning adrenal nodules, radiofrequency ablation offers a less-invasive approach, with results comparable with surgery.
SUMMARY: Radiofrequency ablation of functioning adrenal nodules is a newer application of a technology in use for almost 2 decades. Although limited, reports to date suggest that results are comparable with those of laparoscopic adrenalectomy, but with advantages including being a less-invasive outpatient procedure with lower morbidity, faster recovery, and lower cost. However, the current data are all retrospective, the number of patients treated is small, and reported long-term results are limited.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28248752     DOI: 10.1097/MED.0000000000000329

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  3 in total

1.  Catheter-based adrenal ablation: an alternative therapy for patients with aldosterone-producing adenoma.

Authors:  Fang Sun; Xiaoli Liu; Hexuan Zhang; Xunmei Zhou; Zhigang Zhao; Hongbo He; Zhencheng Yan; Yingsha Li; Qiang Li; Yaoming Li; Jun Jiang; Zhiming Zhu
Journal:  Hypertens Res       Date:  2022-10-14       Impact factor: 5.528

2.  Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial.

Authors:  Hexuan Zhang; Qiang Li; Xiaoli Liu; Zhigang Zhao; Hongbo He; Fang Sun; Yangning Hong; Xunmei Zhou; Yingsha Li; Rufei Shen; Xiaona Bu; Zhencheng Yan; Hongting Zheng; Gangyi Yang; Zhiming Zhu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-27       Impact factor: 3.738

3.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.